RxDoctor Payments Data

John Prieve, DO

Internal Medicine · Phoenix, AZNPI 1609887389

Payments from drug & device makers

$341in general payments, 2019–2025

Across 20 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$97
  • Lilly USA, LLC$76
  • Sanofi-aventis U.S. LLC$30
  • AbbVie$29
  • GSK$25
  • Pfizer$19
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$32997%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead5$97
Lilly USA, LLC5$76
Sanofi-aventis U.S. LLC2$30
AbbVie(2 entities)2$29
GSK1$25
Pfizer1$19
Boehringer Ingelheim1$19
Merck1$17
Novo Nordisk1$17
AstraZeneca1$13

How this compares

$341 in reported general payments places this provider in the 60th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$42,696
Medicare patients
128
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$112,541
OzempicSemaglutide32$82,440
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$44,813
EliquisApixaban37$44,490
MounjaroTirzepatide16$40,814
TrulicityDulaglutide25$33,915
JanuviaSitagliptin Phosphate22$20,584
XareltoRivaroxaban12$16,116
Soliqua 100-33Insulin Glargine/Lixisenatide13$13,482
LinzessLinaclotide11$13,284
Spiriva RespimatTiotropium Bromide14$7,244
Atorvastatin Calcium535$5,709
SymbicortBudesonide/Formoterol Fumarate12$4,286
Gabapentin127$3,689
Albuterol Sulfate HfaAlbuterol Sulfate123$3,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$19$119,78587 claims
Novo NordiskOzempic$17$82,44032 claims
Lilly USA, LLCMounjaro, Trulicity$76$74,72841 claims
GSKTrelegy Ellipta$25$44,81346 claims
PfizerEliquis$19$44,49037 claims
MerckJanuvia$17$20,58422 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$30$15,50933 claims
AbbVieLinzess$29$13,28411 claims
AstraZenecaSymbicort$13$4,28612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →